Cognition Therapeutics (Cognition Therapeutics) FCF Yield % : -26.59 (As of May. 12, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cognition Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Cognition Therapeutics's Trailing 12-Month Free Cash Flow is $-20.66 Mil, and Market Cap is $77.71 Mil. Therefore, Cognition Therapeutics's FCF Yield % for today is -26.59%.

The historical rank and industry rank for Cognition Therapeutics's FCF Yield % or its related term are showing as below:

CGTX' s FCF Yield % Range Over the Past 10 Years
Min: -76.24 Med: 0 Max: 0
Current: -26.59

CGTX's FCF Yield % is ranked worse than
59% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs CGTX: -26.59

Cognition Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

Cognition Therapeutics FCF Yield % Historical Data

The historical data trend for Cognition Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognition Therapeutics FCF Yield % Chart

Cognition Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-2.60

-30.72

-27.17

Cognition Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Yield %	Get a 7-Day Free Trial													-18.95	-26.80	-38.53	-36.88	-39.82

Competitive Comparison of Cognition Therapeutics's FCF Yield %

For the Biotechnology subindustry, Cognition Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cognition Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cognition Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Cognition Therapeutics's FCF Yield % falls into.

Cognition Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Cognition Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-16.165	/	59.506175
	=	-27.17%

Cognition Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-7.244	*	4	/	72.774338
	=	-39.82%

Cognition Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Cognition Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Cognition Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cognition Therapeutics (Cognition Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cognition Therapeutics Inc (NAS:CGTX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2500 Westchester Avenue, Purchase, NY, USA, 10577

Website

https://www.cogrx.com

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Executives

John Brendan Doyle	officer: Chief Financial Officer	C/O CHIASMA INC., 140 KENDRICK STREET BUILDING C EAST, NEEDHAM MA 20494
Lisa Ricciardi	director, officer: CEO & President	C/O COGNITION THERAPEUTICS, INC, 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Anthony Caggiano	officer: Chief Medical Officer	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVENUE, PURCHASE NY 10577
Ellen B Richstone	director	C/O SONUS NETWORKS, INC., 7 TECHNOLOGY PARK DRIVE, WESTFORD MA 01886
Fletcher Aaron G.l.	director	40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis	director, 10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Memory Spv Ii, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Equity Partners Ii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp	10 percent owner	1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Peggy Wallace	director	C/O COGNITION THERAPEUTICS, INC., 2500 WESTCHESTER AVE., PURCHASE NY 10577
Bios Fund Ii Nt, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp	10 percent owner	1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107